Fig. 2.

Heterozygous TRIM16^+/flox mice have decreased latency of papilloma development. a Latency of papilloma development was measured by counting the number of papilloma lesions in each cohort of mice every 3 weeks from week 10–21 following a single dose of 9,10-dimethylbenz[a]anthracene (DMBA) tumour initiation treatment. Topical tumour promoting TPA (12-O-tetradecanoylphorbol-13-acetate) treatment was administered twice weekly. The number of papilloma and mouse genotype is counted over a period of 21 weeks post-DMBA tumour initiation. An ANOVA statistical test was performed to assess significance of change in number of lesions present at each time point. b Representative examples are shown of papilloma (blue arrow) and squamous cell carcinoma (SCC; red arrow) with respective confirmatory histology shown below. c The phenotype incidence per genotype is shown with normal skin (black), papilloma (grey) and SCC (teal) as indicated. d The development of SCC by genotype is shown. Comparison between TRIM16^+/+N = 22, TRIM16^+/floxN = 33 was analysed by Student’s t test P = 0.07